Pharmacogenetics – CYP2D6 and CYP2C19 Genetic Testing

Product detailed description

CYP2D6 and CYP2C19 pharmacogenetic testing helps identify how your genetic makeup may influence the way your body processes certain medications. People can respond differently to the same drug – while a medication may work as expected for one person, another may experience reduced effectiveness or more pronounced side effects. Genetic differences in drug metabolism are one of the reasons behind these variations.

The test analyzes two important genes, CYP2D6 and CYP2C19, which encode enzymes belonging to the cytochrome P450 family. These enzymes are involved in the metabolism of many commonly prescribed medications, including certain antidepressants, antipsychotics, pain medications, proton pump inhibitors, and cardiovascular drugs.

Genetic variations may cause the body to metabolize certain medications more slowly or more rapidly. Depending on the drug, these differences can influence medication concentrations, treatment effectiveness, and the risk of adverse reactions. For some medications, these enzymes are also responsible for converting the drug into its active form.

What does CYP2D6 and CYP2C19 genetic testing evaluate?

• CYP2D6 gene – genetic variants affecting the metabolism of certain antidepressants, antipsychotics, pain medications, and other drugs.

• CYP2C19 gene – genetic variants involved in processing certain antidepressants, proton pump inhibitors, and the antiplatelet medication clopidogrel.

• Drug metabolism rate – inherited differences associated with slower or faster metabolism of selected medications.

• Medication effectiveness and tolerability – genetic factors that may influence treatment response and the likelihood of adverse effects for certain drugs.

• Individual pharmacogenetic profile – information that may help healthcare professionals personalize medication selection and dosing.

Who may benefit from pharmacogenetic testing?

• Individuals taking medications metabolized by CYP2D6 or CYP2C19.

• Patients experiencing unexpected side effects or insufficient treatment response to certain medications.

• People who may be prescribed drugs affected by these enzymes.

• Patients receiving selected psychiatric medications, pain treatments, or other drugs with established pharmacogenetic relevance.

• Individuals interested in personalized medicine and genetic factors influencing medication response.

What can the results reveal?

The CYP2D6 and CYP2C19 genetic test identifies analyzed genetic variants that may influence the activity of these drug-metabolizing enzymes.

Depending on the scope of testing, results may allow prediction of metabolizer status, such as poor, intermediate, normal, rapid, or ultrarapid metabolizer. The applicable categories differ between the two genes.

Combined CYP2D6 and CYP2C19 testing provides a broader pharmacogenetic profile than testing either gene individually. This information may help healthcare professionals make more informed decisions about medication selection, dosage adjustments, and monitoring of treatment effectiveness and safety.

Important: Genetic testing alone cannot determine the most appropriate medication or dosage. Drug response is also influenced by age, medical conditions, liver function, other medications, and additional factors. Pharmacogenetic results are clinically relevant only for medications with established gene–drug associations. Any treatment changes should always be discussed with a qualified healthcare professional. This test does not replace medical care.